Kazutaka Saito

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5870344/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Diagnostic performance of diffusion-weighted magnetic resonance imaging in bladder cancer: potential utility of apparent diffusion coefficient values as a biomarker to predict clinical aggressiveness. European Radiology, 2011, 21, 2178-2186.	4.5	157
2	Incidence of Benign Pathologic Lesions at Partial Nephrectomy for Presumed RCC Renal Masses: Japanese Dual-Center Experience with 176 Consecutive Patients. Urology, 2008, 72, 598-602.	1.0	127
3	Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clinical Cancer Research, 2003, 9, 5501-7.	7.0	115
4	Role of Diffusion-Weighted Magnetic Resonance Imaging in Predicting Sensitivity to Chemoradiotherapy in Muscle-Invasive Bladder Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 83, e21-e27.	0.8	112
5	C-reactive protein as a biomarker for urological cancers. Nature Reviews Urology, 2011, 8, 659-666.	3.8	105
6	Impact of C-Reactive Protein Kinetics on Survival of Patients with Metastatic Renal Cell Carcinoma. European Urology, 2009, 55, 1145-1154.	1.9	104
7	Increased preoperative serum Câ€reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU International, 2007, 99, 77-80.	2.5	103
8	Initial Experience of Diffusion-weighted Magnetic Resonance Imaging to Assess Therapeutic Response to Induction Chemoradiotherapy Against Muscle-invasive Bladder Cancer. Urology, 2010, 75, 387-391.	1.0	97
9	Apparent diffusion coefficient value reflects invasive and proliferative potential of bladder cancer. Journal of Magnetic Resonance Imaging, 2014, 39, 172-178.	3.4	97
10	The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically. BJU International, 2007, 100, 269-273.	2.5	88
11	Reactive oxygen species mediate detrusor overactivity via sensitization of afferent pathway in the bladder of anaesthetized rats. BJU International, 2008, 101, 775-780.	2.5	87
12	Development and External Validation of a New Outcome Prediction Model for Patients With Clear Cell Renal Cell Carcinoma Treated With Nephrectomy Based on Preoperative Serum C-Reactive Protein and TNM Classification: The TNM-C Score. Journal of Urology, 2009, 181, 1004-1012.	0.4	87
13	Computerâ€aided diagnosis of prostate cancer on magnetic resonance imaging using a convolutional neural network algorithm. BJU International, 2018, 122, 411-417.	2.5	84
14	Development, Validation, and Head-to-Head Comparison of Logistic Regression-Based Nomograms and Artificial Neural Network Models Predicting Prostate Cancer on Initial Extended Biopsy. European Urology, 2008, 54, 601-611.	1.9	80
15	LOCALIZATION OF AQUAPORIN-7 IN HUMAN TESTIS AND EJACULATED SPERM: POSSIBLE INVOLVEMENT IN MAINTENANCE OF SPERM QUALITY. Journal of Urology, 2004, 172, 2073-2076.	0.4	73
16	High Diagnostic Ability of Multiparametric Magnetic Resonance Imaging to Detect Anterior Prostate Cancer Missed by Transrectal 12-Core Biopsy. Journal of Urology, 2013, 190, 867-873.	0.4	69
17	Usefulness of Pre-biopsy Multiparametric Magnetic Resonance Imaging and Clinical Variables to Reduce Initial Prostate Biopsy in Men with Suspected Clinically Localized Prostate Cancer. Journal of Urology, 2013, 190, 502-508.	0.4	65
18	Câ€reactive protein level predicts prognosis in patients with muscleâ€invasive bladder cancer treated with chemoradiotherapy. BJU International, 2008, 101, 978-981.	2.5	63

#	Article	IF	CITATIONS
19	Lymphovascular Invasion is Independently Associated With Poor Prognosis in Patients With Localized Upper Urinary Tract Urothelial Carcinoma Treated Surgically. Journal of Urology, 2007, 178, 2291-2296.	0.4	61
20	Prognostic Factors of Patients With Metastatic Renal Cell Carcinoma With Removed Metastases: A Multicenter Study of 556 Patients. Urology, 2013, 82, 846-851.	1.0	61
21	New three-dimensional head-mounted display system, TMDU-S-3D system, for minimally invasive surgery application: Procedures for gasless single-port radical nephrectomy. International Journal of Urology, 2012, 19, 886-889.	1.0	60
22	Prognostic Impact of Postoperative C-Reactive Protein Level in Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy. Journal of Urology, 2008, 180, 515-519.	0.4	59
23	Diffusionâ€weighted magnetic resonance imaging in the differentiation of angiomyolipoma with minimal fat from clear cell renal cell carcinoma. International Journal of Urology, 2011, 18, 727-730.	1.0	58
24	Selective bladderâ€sparing protocol consisting of induction lowâ€dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscleâ€invasive bladder cancer: oncological outcomes of the initial 46 patients. BJU International, 2012, 109, 860-866.	2.5	55
25	Role of Câ€reactive protein in urological cancers: A useful biomarker for predicting outcomes. International Journal of Urology, 2013, 20, 161-171.	1.0	55
26	Prognostic Impact of C-reactive Protein for Determining Overall Survival of Patients With Castration-resistant Prostate Cancer Treated With Docetaxel. Urology, 2011, 78, 1131-1135.	1.0	46
27	Risk stratification for bladder recurrence of upper urinary tract urothelial carcinoma after radical nephroureterectomy. BJU International, 2015, 115, 705-712.	2.5	43
28	Impact of the Prostate Imaging Reporting and Data System, Version 2, on MRI Diagnosis for Extracapsular Extension of Prostate Cancer. American Journal of Roentgenology, 2017, 209, W76-W84.	2.2	42
29	Malignant Clear Cell "Sugar―Tumor of the Kidney: Clear Cell Variant of Epithelioid Angiomyolipoma. Journal of Urology, 2002, 168, 2533-2534.	0.4	41
30	Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. International Journal of Clinical Oncology, 2013, 18, 884-889.	2.2	41
31	Higher Serum C-reactive Protein Level Represents the Immunosuppressive Tumor Microenvironment in Patients With Clear Cell Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2018, 16, e1151-e1158.	1.9	41
32	Progressive Site-Directed Therapy for Castration-Resistant Prostate Cancer: Localization of the Progressive Site as a Prognostic Factor. International Journal of Radiation Oncology Biology Physics, 2019, 105, 376-381.	0.8	41
33	Low-Dose Chemoradiotherapy Followed by Partial or Radical Cystectomy Against Muscle-Invasive Bladder Cancer: An Intent-to-Treat Survival Analysis. Urology, 2008, 72, 384-388.	1.0	40
34	Favourable outcomes of patients with clinical stage T3N0M0 bladder cancer treated with induction lowâ€dose chemoâ€radiotherapy plus partial or radical cystectomy vs immediate radical cystectomy: a singleâ€institutional retrospective comparative study. BJU International, 2009, 104, 189-194.	2.5	40
35	Initial experience of functional imaging of upper urinary tract neoplasm by diffusionâ€weighted magnetic resonance imaging. International Journal of Urology, 2008, 15, 140-143.	1.0	39
36	Apparent diffusion coefficient value as a biomarker reflecting morphological and biological features of prostate cancer. International Urology and Nephrology, 2014, 46, 555-561.	1.4	39

#	Article	IF	CITATIONS
37	Role of C-reactive protein as a biomarker for renal cell carcinoma. Expert Review of Anticancer Therapy, 2010, 10, 1979-1989.	2.4	37
38	Characteristics and clinical significance of prostate cancers missed by initial transrectal $12\hat{a}\in e$ ore biopsy. BJU International, 2012, 109, 665-671.	2.5	36
39	Selective tetramodal bladderâ€preservation therapy, incorporating induction chemoradiotherapy and consolidative partial cystectomy with pelvic lymph node dissection for muscleâ€invasive bladder cancer: oncological and functional outcomes of 107 patients. BJU International, 2019, 124, 242-250.	2.5	35
40	External Validation of the Mayo Clinic Cancer Specific Survival Score in a Japanese Series of Clear Cell Renal Cell Carcinoma. Journal of Urology, 2008, 180, 1290-1296.	0.4	34
41	Longitudinal Change in Renal Function After Radical Nephrectomy in Japanese Patients With Renal Cortical Tumors. Journal of Urology, 2011, 185, 2066-2071.	0.4	34
42	Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab. , 2021, 9, e001564.		34
43	Phaseâ€II trial of combination treatment of interferonâ€Î±, cimetidine, cyclooxygenaseâ€2 inhibitor and reninâ€angiotensinâ€system inhibitor (lâ€CCA therapy) for advanced renal cell carcinoma. Cancer Science, 2011, 102, 137-143.	3.9	33
44	Apparent diffusion coefficient as a prognostic biomarker of upper urinary tract cancer: a preliminary report. European Radiology, 2013, 23, 2206-2214.	4.5	33
45	Perioperative Complications of Radical Cystectomy After Induction Chemoradiotherapy in Bladder-sparing Protocol Against Muscle-invasive Bladder Cancer: A Single Institutional Retrospective Comparative Study with Primary Radical Cystectomy. Japanese Journal of Clinical Oncology 2011 41 1373-1379	1.3	30
46	Prognostic Significance of Endothelial Per-Arnt-Sim Domain Protein 1/Hypoxia-Inducible Factor-2α Expression in a Subset of Tumor Associated Macrophages in Invasive Bladder Cancer. Journal of Urology, 2004, 171, 1080-1084.	0.4	29
47	Equivalent survival and improved preservation of renal function after distal ureterectomy compared with nephroureterectomy in patients with urothelial carcinoma of the distal ureter: A propensity scoreâ€matched multicenter study. International Journal of Urology, 2014, 21, 1098-1104.	1.0	29
48	Development of a nomogram incorporating serum C-reactive protein level to predict overall survival of patients with advanced urothelial carcinoma and its evaluation by decision curve analysis. British Journal of Cancer, 2012, 107, 1031-1036.	6.4	28
49	Impact of Câ€reactive protein kinetics on survival of patients with advanced urothelial carcinoma treated by secondâ€ine chemotherapy with gemcitabine, etoposide and cisplatin. BJU International, 2012, 110, 1478-1484.	2.5	28
50	Combination of Diffusion-weighted Magnetic Resonance Imaging and Extended Prostate Biopsy Predicts Lobes Without Significant Cancer: Application in Patient Selection for Hemiablative Focal Therapy. European Urology, 2014, 65, 186-192.	1.9	28
51	Mixed reality computed tomographyâ€based surgical planning for partial nephrectomy using a headâ€mounted holographic computer. International Journal of Urology, 2019, 26, 681-682.	1.0	28
52	Gasless laparoendoscopic singleâ€port clampless sutureless partial nephrectomy for peripheral renal tumors: Perioperative outcomes. International Journal of Urology, 2015, 22, 349-355.	1.0	27
53	Loss of uroplakin III expression is associated with a poor prognosis in patients with urothelial carcinoma of the upper urinary tract. BJU International, 2006, 97, 1322-1326.	2.5	25
54	Safety of transperineal 14â€core systematic prostate biopsy in diabetic men. International Journal of Urology, 2009, 16, 930-935.	1.0	25

#	Article	IF	CITATIONS
55	Treatment outcome and prognostic factors in renal cell cancer patients with bone metastasis. Clinical and Experimental Metastasis, 2011, 28, 405-411.	3.3	25
56	Antimicrobial Prophylaxis is Not Necessary in Clean Category Minimally Invasive Surgery for Renal and Adrenal Tumors: A Prospective Study of 373 Consecutive Patients. Urology, 2012, 80, 570-575.	1.0	25
57	Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. International Journal of Clinical Oncology, 2017, 22, 1081-1086.	2.2	25
58	Adherent Perinephric Fat in Asian Patients: Predictors and Impact on Perioperative Outcomes of Partial Nephrectomy. Urologia Internationalis, 2018, 101, 437-442.	1.3	25
59	Possible involvement of bone morphogenetic protein 2 in heterotopic ossification in metastatic lesion from urothelial carcinoma of bladder. International Journal of Urology, 2006, 13, 1126-1128.	1.0	24
60	Young Age as Favorable Prognostic Factor for Cancer-specific Survival in Localized Renal Cell Carcinoma. Urology, 2011, 77, 842-847.	1.0	24
61	Renal function after radical nephrectomy: Development and validation of predictive models in <scp>J</scp> apanese patients. International Journal of Urology, 2014, 21, 238-242.	1.0	23
62	High Ki-67 Expression Predicts Favorable Survival in Muscle-Invasive Bladder Cancer Patients Treated With Chemoradiation-Based Bladder-Sparing Protocol. Clinical Genitourinary Cancer, 2015, 13, e243-e251.	1.9	22
63	Utility of computed diffusionâ€weighted MRI for predicting aggressiveness of prostate cancer. Journal of Magnetic Resonance Imaging, 2017, 46, 490-496.	3.4	20
64	Usefulness of the inchworm sign on DWI for predicting pT1 bladder cancer progression. European Radiology, 2019, 29, 3881-3888.	4.5	20
65	Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab. Cancer Immunology, Immunotherapy, 2021, 70, 657-665.	4.2	20
66	Head-Mounted Display for a Personal Integrated Image Monitoring System: Ureteral Stent Placement. Urologia Internationalis, 2015, 94, 117-120.	1.3	19
67	Discarding antimicrobial prophylaxis for transurethral resection of bladder tumor: A feasibility study. International Journal of Urology, 2009, 16, 61-63.	1.0	18
68	Clinical Application of a Modern Highâ€Definition Headâ€Mounted Display in Sonography. Journal of Ultrasound in Medicine, 2014, 33, 1499-1504.	1.7	18
69	Impact of bladder neck involvement on progression in patients with primary non–muscle invasive bladder cancer: A prospective validation study. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 38.e29-38.e36.	1.6	18
70	Diabetes Mellitus with Obesity is a Predictor of Recurrence in Patients with Non-metastatic Renal Cell Carcinoma. Japanese Journal of Clinical Oncology, 2013, 43, 740-746.	1.3	17
71	Impact of Immunohistochemistry-Based Subtypes in Muscle-Invasive Bladder Cancer on Response to Chemoradiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1408-1416.	0.8	17
72	Recovery of renal function after radical nephrectomy and risk factors for postoperative severe renal impairment: A Japanese multicenter longitudinal study. International Journal of Urology, 2016, 23, 219-223.	1.0	15

#	Article	IF	CITATIONS
73	Impact of radiotherapy to the primary tumor on the efficacy of pembrolizumab for patients with advanced urothelial cancer: A preliminary study. Cancer Medicine, 2020, 9, 8355-8363.	2.8	15
74	Spatial and Isoform Specific p63 Expression in the Male Human Urogenital Tract. Journal of Urology, 2006, 176, 2268-2273.	0.4	14
75	Pharmacokinetic–Pharmacodynamic Analysis of Sunitinib-Induced Thrombocytopenia in Japanese Patients with Renal Cell Carcinoma. Biological and Pharmaceutical Bulletin, 2015, 38, 402-410.	1.4	14
76	Ureteral Involvement Is Associated with Poor Prognosis in Upper Urinary Tract Urothelial Carcinoma Patients Treated by Nephroureterectomy: A Multicenter Database Study. European Urology Focus, 2016, 2, 296-302.	3.1	14
77	Stepwise algorithm using computed tomography and magnetic resonance imaging for diagnosis of fatâ€poor angiomyolipoma in small renal masses: Development and external validation. International Journal of Urology, 2017, 24, 511-517.	1.0	14
78	Endoscope-assisted Minilaparotomy (Endoscopic Minilaparotomy) for Retroperitoneal Schwannoma: Experience with Three Cases. Japanese Journal of Clinical Oncology, 2002, 32, 177-180.	1.3	13
79	Favorable Outcome of Preoperative Low Dose Chemoradiotherapy Against Muscle-Invasive Bladder Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 504-507.	1.3	13
80	Oncological outcome of minimum incision endoscopic radical nephrectomy for pathologically organ confined renal cell carcinoma. International Journal of Urology, 2008, 15, 44-47.	1.0	13
81	New head-mounted display system applied to endoscopic management of upper urinary tract carcinomas. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2014, 40, 842-845.	1.5	13
82	Female Gender Predicts Favorable Prognosis in Patients With Non-metastatic Clear Cell Renal Cell Carcinoma Undergoing Curative Surgery: Results From the International Marker Consortium for Renal Cancer (INMARC). Clinical Genitourinary Cancer, 2020, 18, 111-116.e1.	1.9	13
83	Preoperative Elevation of C-Reactive Protein Is a Predictor for Adverse Oncologic Survival Outcomes for Renal Cell Carcinoma: Analysis from the International Marker Consortium Renal Cancer (INMARC). Clinical Genitourinary Cancer, 2021, 19, e206-e215.	1.9	13
84	Effect of Diabetes Mellitus on High-grade Prostate Cancer Detection Among Japanese Obese Patients With Prostate-specific Antigen Less Than 10 ng/mL. Urology, 2012, 79, 1329-1335.	1.0	12
85	Pathologyâ€based risk stratification of muscleâ€invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladderâ€sparing approaches. BJU International, 2012, 110, E203-8.	2.5	12
86	Successful reduction of hospital-acquired methicillin-resistant Staphylococcus aureus in a urology ward: a 10-year study. BMC Urology, 2013, 13, 35.	1.4	12
87	840 NEW THREE-DIMENSIONAL HEAD-MOUNTED DISPLAY SYSTEM (ROBOSURGEON SYSTEM): APPLICATION TO THE INITIAL 80 CASES OF GASLESS SINGLE-PORT ACCESS UROLOGIC SURGERIES. Journal of Urology, 2013, 189, .	0.4	12
88	Impact of Advanced Age on Biochemical Recurrence After Radical Prostatectomy in Japanese Men According to Pathological Stage. Japanese Journal of Clinical Oncology, 2013, 43, 410-416.	1.3	12
89	Significance of Positive Urine Cytology on Progression and Cancer-Specific Mortality of Non–Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer, 2014, 12, e87-e93.	1.9	12
90	METastasis Reporting and Data System for Prostate Cancer as a Prognostic Imaging Marker in Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer, 2020, 18, e391-e396.	1.9	12

#	Article	IF	CITATIONS
91	Increased expression of sialyl-Lewis A correlates with poor survival in upper urinary tract urothelial cancer patients. Anticancer Research, 2003, 23, 3441-6.	1.1	12
92	Progression of hypertension after partial nephrectomy in patients with renal tumors: A preliminary report. International Journal of Urology, 2015, 22, 797-798.	1.0	11
93	Incidence and predictive factors of hypoglycemia after pheochromocytoma resection. International Journal of Urology, 2019, 26, 273-277.	1.0	11
94	Elevated preoperative Câ€reactive protein is associated with renal functional decline and nonâ€cancer mortality in surgically treated renal cell carcinoma: analysis from the INternational Marker Consortium for Renal Cancer (INMARC). BJU International, 2021, 127, 311-317.	2.5	11
95	Malignant clear cell "sugar" tumor of the kidney: clear cell variant of epithelioid angiomyolipoma. Journal of Urology, 2002, 168, 2533-4.	0.4	11
96	Endoscopic Minilaparotomy Partial Nephrectomy for Solitary Renal Cell Carcinoma Smaller than 4 cm. Japanese Journal of Clinical Oncology, 2002, 32, 417-421.	1.3	10
97	Prostateâ€specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castrationâ€resistant prostate cancer. BJU International, 2012, 110, 1149-1155.	2.5	10
98	Sensitivity to chemoradiation predicts development of metastasis in muscle-invasive bladder cancer patients. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1270-1275.	1.6	10
99	Pre-operative Risk Stratification for Cancer-specific Survival in Patients with Renal Cell Carcinoma with Venous Involvement Who Underwent Nephrectomy. Japanese Journal of Clinical Oncology, 2014, 44, 756-761.	1.3	10
100	Candidate selection for quadrantâ€based focal ablation through a combination of diffusionâ€weighted magnetic resonance imaging and prostate biopsy. BJU International, 2016, 117, 94-101.	2.5	10
101	Acute kidney injury and intermediateâ€ŧerm renal function after clampless partial nephrectomy. International Journal of Urology, 2019, 26, 113-118.	1.0	10
102	Extended biopsy based criteria incorporating cumulative cancer length for predicting clinically insignificant prostate cancer. BJU International, 2012, 110, E564-9.	2.5	9
103	Diagnostic performance of initial transperineal 14-core prostate biopsy to detect significant cancer. International Urology and Nephrology, 2013, 45, 645-652.	1.4	9
104	AÂthree-dimensional head-mounted display system (RoboSurgeon system) for gasless laparoendoscopic single-port partial cystectomy. Wideochirurgia I Inne Techniki Maloinwazyjne, 2014, 4, 638-643.	0.7	9
105	Longitudinal change in health-related quality of life after intensity-modulated radiation monotherapy for clinically localized prostate cancer. Quality of Life Research, 2014, 23, 1641-1650.	3.1	9
106	A novel interactive educational system in the operating room–the IE system. BMC Medical Education, 2016, 16, 44.	2.4	9
107	The Diagnostic Accuracy of Testicular Torsion by Doctors on Duty Using Sonographic Evaluation with Color Doppler. American Journal of Men's Health, 2020, 14, 155798832095300.	1.6	9
108	Absence of renal artery pseudoaneurysm on computed tomography after minimallyâ€invasive partial nephrectomy using clampless and sutureless techniques. International Journal of Urology, 2017, 24, 472-473.	1.0	9

#	Article	IF	CITATIONS
109	Favorable response to combination treatment of cimetidine, cyclooxygenaseâ€2 inhibitor and reninâ€angiotensin system inhibitor in metastatic renal cell carcinoma: Report of three cases. International Journal of Urology, 2008, 15, 848-850.	1.0	8
110	History of malignancy is a predictor of prostate cancer detection: Incorporation into a preâ€biopsy nomogram. International Journal of Urology, 2008, 15, 1055-1060.	1.0	8
111	Application of virtual reality in patient explanation of magnetic resonance imaging–ultrasound fusion prostate biopsy. International Journal of Urology, 2020, 27, 471-472.	1.0	8
112	A novel equation and nomogram including body weight for estimating prostate volumes in men with biopsy-proven benign prostatic hyperplasia. Asian Journal of Andrology, 2012, 14, 703-707.	1.6	8
113	miRNA299 involvement in CYP11B2 expression in aldosterone-producing adenoma. European Journal of Endocrinology, 2019, 181, 69-78.	3.7	8
114	Female urethral diverticular abscess clearly depicted by diffusionâ€weighted magnetic resonance imaging. International Journal of Urology, 2008, 15, 460-461.	1.0	7
115	Threeâ€dimensional 26â€core biopsyâ€based patient selection criteria for nerveâ€sparing radical prostatectomy. International Journal of Urology, 2008, 15, 1061-1066.	1.0	7
116	A Novel Approach to Surgical Instructions for Scrub Nurses by Using See-Through–Type Head-Mounted Display. CIN - Computers Informatics Nursing, 2015, 33, 335-338.	0.5	7
117	A Novel Approach to Patient Selfâ€Monitoring of Sonographic Examinations Using a Headâ€Mounted Display. Journal of Ultrasound in Medicine, 2015, 34, 29-35.	1.7	7
118	Feasibility and outcomes of selective tetramodal bladderâ€preservation therapy in elderly patients with muscleâ€invasive bladder cancer. International Journal of Urology, 2020, 27, 236-243.	1.0	7
119	Significance of Bladder Neck Involvement in Risk Substratification of Intermediate-Risk Non–muscle-invasive Bladder Cancer. European Urology Focus, 2021, 7, 366-372.	3.1	7
120	A Novel Repeat Biopsy Nomogram Based on Three-dimensional Extended Biopsy. Urology, 2011, 77, 915-920.	1.0	6
121	Integrated image monitoring system using head-mounted display for gasless single-port clampless partial nephrectomy. Wideochirurgia I Inne Techniki Maloinwazyjne, 2014, 4, 634-637.	0.7	6
122	Novel image monitoring system using a headâ€mounted display for assistants in da Vinci surgery. International Journal of Urology, 2015, 22, 520-521.	1.0	6
123	Multitask Imaging Monitor for Surgical Navigation: Combination of Touchless Interface and Head-Mounted Display. Urologia Internationalis, 2017, 98, 486-488.	1.3	6
124	Potential Utility of Diffusion-Weighted Magnetic Resonance Imaging in Diagnosis of Residual Bladder Cancer before Second Transurethral Resection. Urologia Internationalis, 2017, 98, 298-303.	1.3	6
125	Antitumor Activity and Safety of Enzalutamide After Abiraterone Acetate: Seeking the Optimal Treatment Sequence for Castration-resistant Prostate Cancer Patients. European Urology, 2018, 74, 46-47.	1.9	6
126	Potential for computerâ€aided diagnosis using a convolutional neural network algorithm to diagnose fatâ€poor angiomyolipoma in enhanced computed tomography and T2â€weighted magnetic resonance imaging. International Journal of Urology, 2018, 25, 978-979.	1.0	6

#	Article	IF	CITATIONS
127	Impact of Bladder Neck Involvement on Recurrence in Patients With Non–muscle-invasive Bladder Cancer: An Analysis Based on a Time-dependent Model. Clinical Genitourinary Cancer, 2020, 18, e62-e70.	1.9	6
128	Postoperative renal impairment and longitudinal change in renal function after adrenalectomy in patients with Cushing's syndrome. International Journal of Urology, 2020, 27, 395-400.	1.0	6
129	Outcomes of gasless laparoendoscopic singleâ€port partial nephrectomy in 356 consecutive patients: Feasibility of a clampless and sutureless technique. International Journal of Urology, 2021, 28, 302-307.	1.0	6
130	Impact of lower urinary tract symptoms on prostate cancer risk among <scp>J</scp> apanese men with prostateâ€specific antigen <10 ng/mL and nonâ€suspicious digital rectal examination. International Journal of Urology, 2013, 20, 1163-1168.	1.0	5
131	Novel threeâ€dimensional image system for transurethral surgery. International Journal of Urology, 2015, 22, 714-715.	1.0	5
132	Intensity ratio curve analysis of small renal masses on T2â€weighted magnetic resonance imaging: Differentiation of fatâ€poor angiomyolipoma from renal cell carcinoma. International Journal of Urology, 2018, 25, 554-560.	1.0	5
133	SRY-Positive 46, XX Testicular Disorder of Sexual Development With Leydig Cell Tumor. American Journal of Men's Health, 2020, 14, 155798832097007.	1.6	5
134	Medium-term oncological and functional outcomes of hemi-gland brachytherapy using iodine-125 seeds for intermediate-risk unilateral prostate cancer. Brachytherapy, 2021, 20, 842-848.	0.5	5
135	Disparities in Cancer Specific and Overall Survival Outcomes in African Americans With Renal Cell Carcinoma: Analysis From the International Marker Consortium for Renal Cancer (INMARC). Urology, 2022, 163, 164-176.	1.0	5
136	Interactions between inducible nitric oxide synthase and cyclooxygenaseâ $\in 2$ in response to ischaemiaâ $\in r$ eperfusion of rabbit bladder. BJU International, 2010, 106, 716-722.	2.5	4
137	Bone Abnormal Signal Incidentally Found in Pre-Biopsy Diffusion-Weighted MRI for Suspected Prostate Cancer: What Does It Reflect?. Urologia Internationalis, 2014, 93, 170-175.	1.3	4
138	Patient's Self-monitoring of Transurethral Surgical Images Using a Head-mounted Display. Urology Case Reports, 2015, 3, 27-29.	0.3	4
139	Standardization of the apparent diffusion coefficient value of bladder cancer across different centers: Applicability in predicting aggressive pathologic phenotypes. Clinical Imaging, 2017, 44, 121-126.	1.5	4
140	Renal function after bladderâ€preserving therapy for patients with muscleâ€invasive bladder cancer: Results of selective bladderâ€preserving tetramodality therapy consisting of maximal transurethral resection, induction chemoradiotherapy and partial cystectomy. International Journal of Urology, 2019. 26. 1010-1012.	1.0	4
141	Clinical Outcomes of Patients With Histologic Variants of Urothelial Carcinoma Treated With Selective Tetramodal Bladder-preservation Therapy Incorporating Consolidative Partial Cystectomy. Clinical Genitourinary Cancer, 2020, 18, 268-273.e2.	1.9	4
142	Longitudinal changes in patientâ€reported outcomes after artificial urinary sphincter implantation. LUTS: Lower Urinary Tract Symptoms, 2020, 12, 240-244.	1.3	4
143	Contact with renal sinus is associated with poor prognosis in surgically treated pT1 clear cell renal cell carcinoma. International Journal of Urology, 2020, 27, 657-662.	1.0	4
144	Incidence and Risk Factors of Hypertension Following Partial Nephrectomy in Patients With Renal Tumors: A Cross-sectional Study of Postoperative Home Blood Pressure and Antihypertensive Medications. Clinical Genitourinary Cancer, 2020, 18, e619-e628.	1.9	4

#	Article	IF	CITATIONS
145	Value of extraâ€target prostate biopsy for the detection of magnetic resonance imagingâ€missed adverse pathology according to the Prostate Imaging Reporting and Data System scores: Spatial analysis using magnetic resonance–ultrasound fusion images. International Journal of Urology, 2020, 27, 760-766.	1.0	4
146	Collecting duct carcinoma with acquired cystic disease of the kidney in a longâ€ŧerm hemodialysis patient. International Journal of Urology, 2008, 15, 93-95.	1.0	3
147	Phase II trial of first-line chemotherapy with gemcitabine, etoposide, and cisplatin for patients with advanced urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 35.e1-35.e7.	1.6	3
148	Diagnostic performance and safety of a threeâ€dimensional 14 ore systematic biopsy method. BJU International, 2015, 115, 412-418.	2.5	3
149	Predictive ability of renal cortex enhancement in dynamic computed tomography for residual renal function after nephroureterectomy: Comparison with 99m Tcâ€diethylenetriaminopentacetic acid renography and validation study. International Journal of Urology, 2019, 26, 266-272.	1.0	3
150	Treatmentâ€induced changes in levels of brain natriuretic peptide in prostate cancer patients receiving gonadotropinâ€releasing hormone antagonists or agonists. International Journal of Urology, 2020, 27, 354-355.	1.0	3
151	Diagnostic contribution of C-reactive protein kinetics for gastric metastasis from renal cell carcinoma. International Cancer Conference Journal, 2012, 1, 93-95.	0.5	2
152	Performance of prostateâ€specific antigen mass in estimation of prostate volume in Japanese men with benign prostate hyperplasia. International Journal of Urology, 2012, 19, 929-935.	1.0	2
153	PD13-06 FAVORABLE OUTCOMES OF GASLESS SINGLE-PORT CLAMPLESS PARTIAL NEPHRECTOMY USING NEW THREE DIMENSIONAL HEAD-MOUNTED DISPLAY SYSTEM (ROBOSURGEON SYSTEM). Journal of Urology, 2014, 191, .	0.4	2
154	Realâ€time threeâ€dimensional image angle rectification to improve hand–eye coordination in singleâ€port laparoendoscopic surgery. International Journal of Urology, 2017, 24, 639-640.	1.0	2
155	Prediction of Intraoperative Urinary Collecting System Entry in Patients with Peripheral Renal Tumors Undergoing Partial Nephrectomy: Usefulness of Tumor-Centered Multiplanar Reconstruction. Urologia Internationalis, 2018, 100, 85-91.	1.3	2
156	Application of eye tracking as a user interface for urological surgery. International Journal of Urology, 2019, 26, 680-681.	1.0	2
157	Renal epithelioid angiomyolipoma: Incidence in a Japanese cohort and diagnostic utility of diffusionâ€weighted magnetic resonance imaging. International Journal of Urology, 2020, 27, 599-604.	1.0	2
158	Gasless Single-Port RoboSurgeon Retroperitoneoscopic Partial Nephrectomy. , 2015, , 43-64.		2
159	External validation of TNM-C score in three community hospital cohorts for clear cell renal cell carcinoma. Anticancer Research, 2014, 34, 921-6.	1.1	2
160	1172 ANTIBIOTIC PROPHYLAXIS IS NOT NECESSARY IN MINIMALLY INVASIVE SURGERY FOR RENAL AND ADRENAL TUMORS: A PROSPECTIVE STUDY OF 301 CONSECUTIVE PATIENTS. Journal of Urology, 2011, 185, .	0.4	1
161	1105 GASLESS SINGLE-PORT CLAMPLESS PARTIAL NEPHRECTOMY FOR PERIPHERAL RENAL TUMOR SURGICAL, SHORT-TERM ONCOLOGICAL, AND FUNCTIONAL OUTCOMES. Journal of Urology, 2012, 187, .	0.4	1
162	Gasless Single Port Surgery for Renal Cell Carcinoma: Minimum Incision Endoscopic Surgery. , 2012, , .		1

#	Article	IF	CITATIONS
163	49 THE ABNORMALITY OF GLUCOSE TOLERANCE TEST IN PHEOCHROMOCYTOMA: ONE OF THE SIGNIFICANT FINDINGS OF POSTOPERATIVE HYPOGLYCEMIA. Journal of Urology, 2013, 189, .	0.4	1
164	MP8-09 ANTIMICROBIAL PROPHYLAXIS IS AVOIDABLE IN MINIMALLY INVASIVE NEPHROURETERECTOMY WITH NEGATIVE URINE CULTURE. Journal of Urology, 2014, 191, .	0.4	1
165	Combined resection of a tumor and the inferior vena cava: report of two cases. Surgery Today, 2014, 44, 166-170.	1.5	1
166	Re: Nephron-sparing Techniques Independently Decrease the Risk of Cardiovascular Events Relative to Radical Nephrectomy in Patients with a T1a–T1b Renal Mass and Normal Preoperative Renal Function. European Urology, 2016, 69, 538.	1.9	1
167	Potential of Perfusion Magnetic Resonance Imaging to Predict Residual Renal Function after Radical Nephroureterectomy. Urologia Internationalis, 2021, 105, 507-513.	1.3	1
168	Nonmetastatic castrationâ€resistant prostate cancer treated with salvage focal brachytherapy after external beam radiotherapy. IJU Case Reports, 2021, 4, 228-230.	0.3	1
169	Gasless Single-Port RoboSurgeon Retroperitoneoscopic Adrenalectomy. , 2015, , 85-104.		1
170	Association of elevated C-reactive protein with oncologic outcomes in renal CELL carcinoma: A multicenter analysis Journal of Clinical Oncology, 2019, 37, 596-596.	1.6	1
171	Gasless Two-Port Access RoboSurgeon Retroperitoneoscopic Radical Nephroureterectomy. , 2015, , 65-84.		1
172	Gasless Single-Port RoboSurgeon Total Cystectomy with Urinary Diversion. , 2015, , 127-141.		1
173	Association of De Ritis Ratio and Neutrophil Lymphocyte Ratio with renal functional decline and all-cause mortality in renal cell carcinoma Journal of Clinical Oncology, 2020, 38, 741-741.	1.6	1
174	Prognostic Significance of C-reactive Protein in Patients With Non-metastatic Papillary Renal Cell Carcinoma: Results from the INternational Marker Consortium for Renal Cancer (INMARC) Cohort. Clinical Genitourinary Cancer, 2022, 20, e276-e282.	1.9	1
175	Editorial Comment to Nomogram to predict seminal vesicle invasion using the status of cancer at the base of the prostate on systematic biopsy. International Journal of Urology, 2010, 17, 540-540.	1.0	0
176	Editorial Comment from Dr Saito to Impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy. International Journal of Urology, 2012, 19, 1059-1059.	1.0	0
177	CRP kinetics could be prognostic predictors in urothelial cancer. Nature Reviews Urology, 2013, 10, 182-182.	3.8	0
178	Reply to Umberto Capitanio, Paolo Dell'Oglio, Alessandro Larcher, and Francesco Montorsi's Reply to Kazutaka Saito's Words of Wisdom re: Nephron-sparing Techniques Independently Decrease the Risk of Cardiovascular Events Relative to Radical Nephrectomy in Patients with a T1a–T1b Renal Mass and Normal Preoperative Renal Function. Eur Urol. 2016;69:538. European Urology, 2016, 70, e99.	1.9	0
179	Re: Evaluation of Functional Outcomes After Laparoscopic Partial Nephrectomy Using Renal Scintigraphy: Clamped vs. Clampless Technique. European Urology, 2016, 69, 753.	1.9	0
180	Local Treatment of the Prostate in Metastatic Prostate Cancer: Need to Change the Concept?. European Urology, 2017, 72, 20-21.	1.9	0

#	Article	IF	CITATIONS
181	Impact of fluorodeoxyglucose uptake on positron emission tomography/computed tomography on chemosensitivity and survival in patients with metastatic urothelial carcinoma. International Journal of Urology, 2019, 26, 820-826.	1.0	0
182	Nonuse of antimicrobial prophylaxis in clean surgeries for adrenal and renal tumors: Results of the riskâ€based strategy in 1362 consecutive patients. International Journal of Urology, 2021, 28, 1032-1038.	1.0	0
183	IFNy enhances the cytotoxicity of 5-fluorouracil against human bladder cancer cells through induction of PD-ECGF / TP. Japanese Journal of Urology, 2002, 93, 323.	0.1	0
184	Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in primary bladder cancer. Japanese Journal of Urology, 2002, 93, 377.	0.1	0
185	Application of the RoboSurgeon System in Medical Care. , 2015, , 175-184.		0
186	Gasless Single-Port RoboSurgeon Retroperitoneoscopic Radical Nephrectomy. , 2015, , 23-42.		0
187	Gasless Single-Port RoboSurgeon Partial Cystectomy: A Hybrid Technique Combining an Intravesical and Extravesical Approach. , 2015, , 143-158.		0
188	Gasless Single-Port RoboSurgeon Retroperitoneoscopic Radical Prostatectomy. , 2015, , 105-126.		0
189	Gasless Single-Port RoboSurgeon Retroperitoneoscopic Pelvic Lymph Node Dissection and Inguinal Hernia Prevention. , 2015, , 159-173.		0
190	Disparities in survival outcomes in African Americans in renal cell carcinoma: Impact of oncological versus nononcological factors Journal of Clinical Oncology, 2019, 37, 595-595.	1.6	0
191	Clinical outcomes of muscle-invasive bladder cancer patients with hydronephrosis treated with tetra-modality bladder sparing therapy incorporating consolidative partial cystectomy Journal of Clinical Oncology, 2019, 37, 430-430.	1.6	0
192	Development and validation of a novel scoring index (C-reactive protein, age, race, and tumor size) to predict renal functional decline post partial nephrectomy Journal of Clinical Oncology, 2019, 37, 597-597.	1.6	0
193	Impact of diabetes mellitus on functional and survival outcomes in renal cell carcinoma: An international multicenter study Journal of Clinical Oncology, 2020, 38, 666-666.	1.6	0
194	Impact of oncological versus nononcological on survival outcomes in African Americans with renal cell carcinoma Journal of Clinical Oncology, 2020, 38, 749-749.	1.6	0
195	Differences in CRP and De Ritis ratio predictive abilities of cancer specific survival between ethnic groups Journal of Clinical Oncology, 2022, 40, 394-394.	1.6	0
196	Impact of age on functional decline following radical nephrectomy: Analysis of the International Marker Consortium for Renal Cancer (INMARC) Journal of Clinical Oncology, 2022, 40, 395-395.	1.6	0
197	Does presence of diabetes mellitus impact patient oncological outcomes in renal cell carcinoma: A multicenter analysis Journal of Clinical Oncology, 2022, 40, 325-325.	1.6	0